FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 140 filers reported holding FATE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.61 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $773,000 | -58.3% | 49,796 | -45.5% | 0.38% | -52.3% |
| Q2 2019 | $1,854,000 | +15.5% | 91,332 | 0.0% | 0.79% | +11.0% |
| Q1 2019 | $1,605,000 | +21.3% | 91,332 | -11.4% | 0.71% | -1.9% |
| Q4 2018 | $1,323,000 | -21.2% | 103,125 | 0.0% | 0.72% | +6.3% |
| Q3 2018 | $1,680,000 | +90.3% | 103,125 | +32.4% | 0.68% | +58.0% |
| Q2 2018 | $883,000 | +16.2% | 77,889 | 0.0% | 0.43% | +9.4% |
| Q1 2018 | $760,000 | – | 77,889 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |